Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2014

Dec 5, 2014

30016_dirs_2014-12-05_619dd8ca-b9ff-416f-a406-99131dc34f0c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2014-12-03

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-12-03 Common Stock M 29000 $28.655 Acquired 445081 Direct
2014-12-03 Common Stock S 10958 $148.1178 Disposed 434123 Direct
2014-12-03 Common Stock S 18042 $148.7208 Disposed 416081 Direct
2014-12-04 Common Stock M 15000 $34.37 Acquired 431081 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-12-03 Non-Qualified Stock Option (right to buy) $28.6550 M 29000 Disposed 2015-02-02 Common Stock (29000) Direct
2014-12-04 Non-Qualified Stock Option (right to buy) $34.37 M 15000 Disposed 2016-02-13 Common Stock (15000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 49000 Indirect

Footnotes

F1: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $147.49 to $148.48, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $148.49 to $149.00, inclusive.

F4: Grant of options to buy shares of common stock that became exercisable as to 20,000 shares on 02/03/2006, 02/03/2007, 02/03/2008 and 02/03/2009, and the remaining 16,512 shares on 02/03/2010.

F5: Grant of options to buy shares of common stock that became exercisable as to 15,999 shares on 02/14/2010 and 02/14/2013, 16,000 shares on 02/14/2011 and 02/14/2012, and the remaining 13,091 shares on 02/14/2014.